Results 11 to 20 of about 743 (109)

Increase of Brivaracetam serum concentration with introduction of Cenobamate [PDF]

Frontiers in Pharmacology
IntroductionCenobamate is a new antiseizure medication approved for polytherapy of focal epilepsy with complex hepatic metabolism and effects on liver enzymes.
Lena Bender, Martin Hirsch, Andreas Schulze-Bonhage   +2 more
doaj   +2 more sources

A prospective, observational, multicentre study to evaluate the efficacy of brivaracetam as adjuvant therapy for epilepsy: The Bravo study

Drugs in Context
Background: Epilepsy is a persistent tendency to experience epileptic seizures and can lead to various neurobiological disorders, with an elevated risk of premature mortality. This study evaluates the efficacy of brivaracetam adjuvant therapy in patients
Fowzia Siddiqui, Bashir A Soomro, Ehsan U Rehman, Ahsan Numan, Safia Bano, Jawwad Us Salam, Hazim Brohi, Muhammad Zaheer, Faizan Hyder Memon, Muhammad Wahab Qureshi, Junaid Ahmed Sheikh, Abdul Latif Sunejo, Amjad Iqbal, Saira Abbass, Saba Zaidi, Sidrah Nawaz, Kaukab Fatima, Samar Altaf, Neeta Maheshwary, Muhammad Athar Khan, Arjumand Ahmed, Muhammad Iqbal Asif   +21 more
doaj   +2 more sources

Brivaracetam in Combination with Midazolam and Ketamine Reduces Soman-Induced Seizure and Neurodegeneration in Rats

Neurology International
Background/Objective: Status epilepticus (SE) is a life-threatening condition that requires immediate response to effectively control. Although benzodiazepines are the first-line treatment against SE, when treatment is delayed, benzodiazepine ...
Lucille A. Lumley, Hailey G. Steier, Sabrina Y. Orta, Donna A. Nguyen, Michael F. Stone, Caroline R. Schultz, Jerome Niquet, Marcio de Araujo Furtado, Claude G. Wasterlain   +8 more
doaj   +2 more sources

In vitro antineoplastic effects of brivaracetam and lacosamide on human glioma cells

Journal of Experimental & Clinical Cancer Research, 2017
Background Epilepsy is a frequent symptom in patients with glioma. Although treatment with antiepileptic drugs is generally effective in controlling seizures, drug-resistant patients are not uncommon.
Ambra Rizzo, Sara Donzelli, Vita Girgenti, Andrea Sacconi, Chiara Vasco, Andrea Salmaggi, Giovanni Blandino, Marta Maschio, Emilio Ciusani   +8 more
doaj   +2 more sources

Brivaracetam for spinal cord injury–related neuropathic pain: results of a pilot double-blinded, randomized, placebo-controlled clinical trial [PDF]

PAIN Reports
. Objective:. Assess feasibility, safety, and tolerability of 3 months of oral brivaracetam for severe (9–10/10) spinal cord injury–related neuropathic pain. Methods:.
Leslie R. Morse, Ricardo A. Battaglino, Nguyen Nguyen, Brian DeVries, Abigail Welch, Ana Lucia Battaglino, Clas Linnman, Michael Stillman, Robert Wudlick, Joda Glossner, Grant Anderton, Richard Goldstein, Scott P. Falci   +12 more
doaj   +3 more sources

A New Chemoenzymatic Synthesis of the Chiral Key Intermediate of the Antiepileptic Brivaracetam [PDF]

Molecules, 2018
Brivaracetam is a new anticonvulsant compound, recently approved as an antiepileptic drug. This drug substance presents a 4-substituted pyrrolidone structure: the (4R)-configuration of the stereocenter present on the heterocyclic ring is the main target ...
Samuele Ciceri, Paride Grisenti, Shahrzad Reza Elahi, Patrizia Ferraboschi   +3 more
doaj   +2 more sources

Adjunctive Brivaracetam in People with Epilepsy and Intellectual Disability: Evidence from the BRIVAracetam Add-On First Italian netwoRk Study [PDF]

Neurology and Therapy
Introduction Subjects with intellectual disability are usually excluded from clinical trials and there is limited evidence-based guidance for the choice of antiseizure medications in this vulnerable population.
Simona Lattanzi, Laura Canafoglia, Maria Paola Canevini, Sara Casciato, Emanuele Cerulli Irelli, Valentina Chiesa, Filippo Dainese, Giovanni De Maria, Giuseppe Didato, Giancarlo Di Gennaro, Giovanni Falcicchio, Martina Fanella, Edoardo Ferlazzo, Massimo Gangitano, Angela La Neve, Oriano Mecarelli, Elisa Montalenti, Alessandra Morano, Federico Piazza, Chiara Pizzanelli, Patrizia Pulitano, Federica Ranzato, Eleonora Rosati, Laura Tassi, Carlo Di Bonaventura, on behalf of BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST) Group Membership   +25 more
doaj   +4 more sources

New developments in the management of partial-onset epilepsy: role of brivaracetam

Drug Design, Development and Therapy, 2017
Giangennaro Coppola,1 Giulia Iapadre,2 Francesca Felicia Operto,1 Alberto Verrotti2 1Unit of Child and Adolescent Neuropsychiatry, Department of Medicine and Surgery, University of Salerno, Salerno, 2Department of Pediatrics, University of L&rsquo ...
Coppola G, Iapadre G, Operto FF, Verrotti A   +3 more
doaj   +3 more sources

Brivaracetam and topiramate serum levels during pregnancy and delivery: a case report and a review of literature

Neurological Research and Practice
Background An increasing use of newer antiseizure medication (ASM) such as SV2A ligand brivaracetam is observed. However, data on newer antiseizure medication and therapeutic drug monitoring during pregnancy is scarce. Methods Therapeutic drug monitoring
Wiebke Hahn, Leona Möller, Katja Menzler, Tobias Poeplau, Uwe Wagner, Susanne Knake   +5 more
doaj   +2 more sources

Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures [Corrigendum]

Drug Design, Development and Therapy, 2015
Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures [Corrigendum] Mumoli L, Palleria C, Gasparini S, et al. Drug Des Devel Ther. 2015;9:5719–5725.
Mumoli L, Palleria C, Gasparini S, Citraro R, Labate A, Ferlazzo E, Gambardella A, De Sarro G, Russo E   +8 more
doaj   +1 more source